Gail J. Roboz
Director of the Clinical and Translational Leukemia Program · Weill Medical College of Cornell University and the NewYork-Presbyterian Hospital
Credentials: · · · · ·
History
- Present
Clinical and Translational Leukemia Program · Weill Medical College of Cornell University and the NewYork-Presbyterian Hospital
1997–2000- 1995–1997
- 1994–1995
The Beth Israel Hospital
1990
Research
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia
Science Translational Medicine · 2014 · 2,062 citations
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
New England Journal of Medicine · 2018 · 1,234 citations
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Blood · 2017 · 1,232 citations
55 papers
- RK
48 papers
45 papers
44 papers
- AD
42 papers
- DS
39 papers
38 papers
29 papers · 1 as a fellow
Clinical trials
- 2022–2027
A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)
Principal investigator · Recruiting · Phase 1
Bio-Path Holdings, Inc.
- 2017–2025
Principal investigator · Active not recruiting · Phase 1
Cellectis S.A.
- 2015–2017
Study of Clinical Efficacy and Safety of Tosedostat in MDS
Principal investigator · Completed · Phase 2
Weill Medical College of Cornell University
- 2013–2015
Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy
Principal investigator · Completed · Phase 1, Phase 2
Weill Medical College of Cornell University